Abstract 10P
Background
Multi-gene expression tests have been widely accepted as risk-prediction tools in early-stage HR-positive and HER2-negative (HR+/HER2-) breast cancer (EBC) after surgery. This study compared the performance of the 28-gene panel that developed from the Asian breast cancer population with the 70-gene panel in Chinese women with EBC.
Methods
Pts with EBC, previously undergone 70-gene testing after primary surgery from Jan 2019 to Oct 2022 were enrolled. FFPE of primary breast tumors were collected for 28-gene testing. Clinicopathological risk factors such as diagnosed age ≤40y, ≥T2, N1, LVI positive, grade III, Ki-67≥ 20% were included in the final analyses. Pts with clinicopathological risk factors ≥2 were clinical high-risk (n=48); others were low-risk (n=51).
Results
A total of 99 Chinese pts with EBC (pT1-2N0-1 or pT3N0M0) were enrolled in this study, with a median diagnosed age of 52 years (29-74 years). The median follow-up period was 38 months, and the last follow-up date was June 20, 2023. Two pts were lost to follow-up, but none recurred or died. The 28-gene and 70-gene panels detected high-risk pts (26% vs. 34%) and low-risk (73% vs. 65%), respectively. The overall agreement of the two tests was 72% (71/99). In addition, the 28-gene panel showed higher consistency with clinical-risk prediction than the 70-gene panel (Kappa: 0.51 vs. 0.39). Among them, the consistency of the 28-gene panel and 70-gene panel with the low clinical-risk prediction was 98% (50/51) and 84% (43/51), respectively; the high-risk prediction was 47% (25/48) and 54% (26/48), respectively. Table: 10P
Risk prediction comparison of 28-gene and 70-gene panels
| Characteristic | 28-gene (%) | Kappa | 70-gene (%) | Kappa | |||
| High-risk | Low-risk | High-risk | Low-risk | ||||
| Clinical | High-risk | 25(25) | 23(23) | 0.51 | 26(26) | 22(22) | 0.39 |
| Low-risk | 1(1) | 50(51) | P<0.001 | 8(8) | 43(43) | P<0.001 | |
| Total | 26(26) | 73(74) | 99(100) | 34(34) | 65(66) | 99(100) |
Conclusions
The performance of the 28-gene panel in risk prediction of EBC was comparable with the 70-gene panel. The 28-gene panel could identify a more low-risk population in Chinese breast cancer pts. An enlarged sample size and longer follow-up for clinical outcomes will further confirm our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key Research and Development Program of China (2019YFE0196500).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract